International Flavors & Fragrances (IFF)

NYSE Materials Specialty Chemicals S&P 500
$82.62
-3.74 (-4.33%)
Close of Nov 06, 2026 · end-of-day data

IFF 8-K filings in 2025

Every material Form 8-K International Flavors & Fragrances filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.

Briefs in 20251017 on record in all
Latest filing in 2025Nov 04, 2025earnings
High impact (4-5)2of 10 briefs
ToneMixed4Neutral6
leadership 6earnings 4
Nov 4, 4:21 PM ET

IFF Q3 sales fall 8% to $2.69 billion; full-year 2025 guidance reaffirmed

Mixed earnings Written later 2.02

IFF reported third quarter 2025 results, with reported net sales down 8% to $2.69 billion and reported diluted EPS of $0.16 versus $0.23 a year earlier. The company reaffirmed its full-year 2025 sales and adjusted operating EBITDA guidance and said it will revise prior-period financial statements for income tax errors in its Form 10-Q, expected by November 10, 2025.

  • Q3 reported net sales $2.69 billion, down 8%; comparable currency neutral sales were flat
  • Q3 reported diluted EPS $0.16 vs $0.23 a year earlier; adjusted EPS excluding amortization $1.05; adjusted operating EBITDA $519 million
  • Full-year 2025 guidance reaffirmed: sales $10.6 billion to $10.9 billion and adjusted operating EBITDA $2 billion to $2.15 billion
  • Nine-month results include a $1.153 billion goodwill impairment and a net loss attributable to IFF shareholders of $392 million
Read the filing on SEC.gov ↗
Oct 22, 4:15 PM ET

IFF board changes: Brett Icahn and Richard Mulligan join, two directors step down

Neutral leadership Written later 5.02

Two directors, Vincent Intrieri and Margarita Paláu-Hernández, stepped down from the IFF board on October 20, 2025, with the filing stating their departures did not result from any disagreement with the company. Brett Icahn and Dr. Richard Mulligan were appointed to the board effective immediately, under the company's cooperation agreement with the Icahn Group, which changes the board's composition but does not report any financial results or guidance.

  • Vincent Intrieri stepped down from the board on October 20, 2025; Brett Icahn replaces him as the Icahn Designee director
  • Margarita Paláu-Hernández stepped down on October 20, 2025; Dr. Richard Mulligan replaces her as an independent director
  • Brett Icahn joins the Audit Committee and Transaction Committee; Dr. Mulligan joins the Innovation Committee
  • Both new directors will receive the non-employee director compensation described in the 2024 Proxy Statement filed March 18, 2025
Read the filing on SEC.gov ↗
Aug 7, 4:31 PM ET

IFF Names Marc Birenkrant Controller and Chief Accounting Officer, Effective August 10

Neutral leadership Written later 5.02

International Flavors & Fragrances appointed Marc Birenkrant as Controller and Chief Accounting Officer, effective August 10, 2025, replacing Beril Yildiz, who leaves the company as of December 31, 2025. Mr. Birenkrant has been with IFF since 2008 and previously held accounting roles at The Wendy's Company. The change concerns the company's top accounting position and does not include any financial results.

  • Marc Birenkrant appointed Controller and Chief Accounting Officer, effective August 10, 2025
  • Mr. Birenkrant has worked at IFF since 2008, most recently in roles including Vice President, Assistant Controller, and Finance Director
  • He replaces Beril Yildiz, SVP, Controller and Chief Accounting Officer since 2022, who will leave IFF as of December 31, 2025
  • Ms. Yildiz's departure qualifies as an event under the company's executive severance policy
Read the filing on SEC.gov ↗
Aug 5, 4:26 PM ET

IFF Q2 reported EPS rose to $2.38 from $0.66 as sales fell 4%; $500M buyback approved

Mixed earnings Written later 2.028.01

IFF reported second-quarter 2025 net sales of $2.76 billion, down 4% from a year earlier, while reported diluted EPS was $2.38 versus $0.66 a year earlier. The company reaffirmed its full-year 2025 guidance, authorized a $500 million share repurchase program with no set end date, and agreed to sell its soy crush, concentrates and lecithin business to Bunge, which the company said generated about $240 million in 2024 revenue. For shareholders, first-half results include a $1,153 million goodwill impairment that produced a $405 million net loss for the six months.

  • Q2 net sales $2.76 billion, down 4% reported; up 3% on a comparable currency-neutral basis
  • Q2 reported diluted EPS $2.38 versus $0.66 a year earlier; first-half EPS was a loss of $1.59
  • Board authorized up to $500 million in share repurchases with no specified term or termination date
  • Full-year 2025 guidance reaffirmed: sales of $10.6 billion to $10.9 billion and adjusted operating EBITDA of $2 billion to $2.15 billion
Read the filing on SEC.gov ↗
Jul 30, 4:11 PM ET

IFF adds Jesus Mantas and Paul Fribourg to board of directors effective July 29, 2025

Neutral leadership Written later 5.02

International Flavors & Fragrances appointed two new independent directors, Jesus Mantas and Paul Fribourg, effective July 29, 2025. Mantas joins the Audit and Innovation Committees and Fribourg joins the Transaction Committee, and the board determined both meet New York Stock Exchange independence rules. The filing discloses no financial results, and the appointments do not change reported financial figures.

  • Jesus Mantas, 56, formerly Global Managing Partner at IBM Consulting, named to Audit and Innovation Committees
  • Paul Fribourg, 71, Chairman and CEO of Continental Grain Company since 1976, named to Transaction Committee
  • Both directors will receive non-employee director compensation described in the 2024 Proxy Statement filed March 18, 2025
  • Filing reports no related-person transactions above $120,000 involving either director
Read the filing on SEC.gov ↗
Jun 9, 4:28 PM ET

IFF appoints Virginia Drosos, former Signet CEO, to board effective June 16, 2025

Neutral leadership Written later 5.02

International Flavors & Fragrances announced that Virginia Drosos will join its board of directors effective June 16, 2025, and will serve on the Audit, Human Capital & Compensation, and Innovation Committees. The board has determined she is independent under New York Stock Exchange rules, and she will receive the standard non-employee director compensation described in the 2024 proxy statement.

  • Virginia Drosos, 62, joins the IFF board effective June 16, 2025.
  • She will serve on the Audit, Human Capital & Compensation, and Innovation Committees.
  • Previously CEO and director of Signet Jewelers from August 2017 to November 2024.
  • The board determined she is independent under NYSE rules.
Read the filing on SEC.gov ↗
May 6, 4:22 PM ET

IFF reports $994 million pre-tax loss on $1.15 billion goodwill impairment

Mixed earnings Written later 2.02

IFF reported a first-quarter 2025 GAAP loss before taxes of $994 million and a diluted loss of $3.98 per share, driven by a $1.15 billion goodwill impairment in Food Ingredients. Reported net sales fell 2% to $2.84 billion, while adjusted EPS excluding amortization was $1.20 and the company kept its full-year 2025 guidance ranges unchanged.

  • Reported net sales were $2.84 billion, down 2% from the prior-year period; comparable currency neutral sales rose 3%.
  • Reported diluted EPS was $(3.98), versus $0.23 a year earlier; adjusted EPS excluding amortization was $1.20, versus $1.13 in the prior-year period.
  • Adjusted operating EBITDA was $578 million; the company maintained full-year 2025 sales guidance of $10.6 billion to $10.9 billion.
  • The Pharma Solutions divestiture closed on May 1, 2025, earlier than anticipated.
Read the filing on SEC.gov ↗
Mar 13, 6:08 AM ET

IFF General Counsel Jennifer Johnson resigns, will stay through July 1, 2025

Neutral leadership Written later 5.02

International Flavors & Fragrances disclosed that Executive Vice President, General Counsel and Corporate Secretary Jennifer Johnson resigned on March 12, 2025. She will remain employed through July 1, 2025 to ensure a smooth transition, and the company says her departure qualifies as an event under its executive severance policy. The filing does not name a successor or report any financial results.

  • Jennifer Johnson resigned as Executive Vice President, General Counsel and Corporate Secretary on March 12, 2025.
  • Johnson will remain employed with the company through July 1, 2025 to support a transition.
  • Her resignation is a qualifying event under IFF's executive severance policy.
  • The filing does not name a replacement or disclose severance amounts.
Read the filing on SEC.gov ↗
Feb 20, 4:49 PM ET

IFF: President of Health & Biosciences Simon Herriott to leave March 31, 2025

Neutral leadership Written later 5.02

IFF said Simon Herriott, its President of Health & Biosciences, will leave the company on March 31, 2025, and that his departure qualifies under the company's executive severance policy. Leticia Goncalves Lourenço will join as President of the Health & Biosciences division effective March 1, 2025, so the division will have a successor in place before Herriott's exit.

  • Simon Herriott, President, Health & Biosciences, leaves IFF on March 31, 2025
  • His departure is treated as a qualifying event under IFF's executive severance policy
  • Leticia Goncalves Lourenço joins IFF as President, Health & Biosciences, effective March 1, 2025
Read the filing on SEC.gov ↗
Feb 18, 4:27 PM ET

IFF reports flat 2024 sales of $11.48 billion; Q4 net loss of $0.18 per share

Mixed earnings Written later 2.02

International Flavors & Fragrances reported fourth quarter and full year 2024 results on February 18, 2025. Full year reported EPS was $0.95 versus a loss of $10.05 in 2023, which included a $2.6 billion goodwill impairment, while fourth quarter reported EPS was a loss of $0.18 on fourth quarter sales up 3% to $2.77 billion. For 2025 the company guided to sales of $10.6 billion to $10.9 billion and adjusted operating EBITDA of $2 billion to $2.15 billion, with the Pharma Solutions divestiture assumed to close June 30, 2025.

  • Full year 2024 reported sales were $11.48 billion, flat versus 2023; comparable currency neutral sales rose 6%.
  • Full year 2024 reported EPS was $0.95 versus a loss of $10.05 in 2023; adjusted EPS excluding amortization was $4.31.
  • Fourth quarter 2024 reported loss before taxes was $(115) million; reported EPS was $(0.18).
  • 2025 guidance: sales of $10.6 billion to $10.9 billion and adjusted operating EBITDA of $2 billion to $2.15 billion.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every International Flavors & Fragrances filing is on SEC EDGAR ↗. 8-K briefs of other companies →